Format for

**Socio-economic analysis**

**Legal name of applicant(s):** [Legal names of applicant(s)/authorisation holders]

**Submitted by:**  [Legal name of submitting applicant/authorisation holders]

**Date:** [Date when the document was completed, normally the date of submission]

**Substance:**  [Include Annex XIV substance name, EC and CAS number]

**Use title:**  [Include use title]

[This format is for one use. If an application/review report has several uses, separate documents would need to be prepared]

**Use number:**  [Include the number for this use as stated in section 3.10 of the IUCLID application for authorisation dossier under the "Use concerned by the request" field]

CONTENTS

[Please insert here the table of contents]

**TABLES**

[Please insert here the list of tables]

**FIGURES**

[Please insert here the list of figures]

# LIST OF ABBREVIATIONS

[Please insert here the list of abbreviations]

# Declaration

The Applicant is aware of the fact that evidence might be requested by ECHA to support information provided in this document.

Also, we request that the information blanked out in the “public version” of the Socio-economic analysis is not disclosed. We hereby declare that, to the best of our knowledge as of today ([DATE]) the information is not publicly available, and in accordance with the due measures of protection that we have implemented, a member of the public should not be able to obtain access to this information without our consent or that of the third party whose commercial interests are at stake.

Signature: Date, Place:

[NAME, TITLE]

# SUMMARY OF Socio-Economic Analysis

[Insert text here]

# Aims and scope of SEA

## Aims and scope of SEA

[Insert text here]

## Market and business trends including the use of the substance

[Insert text here]

## Definition of “applied for use” scenario

[Insert text here]

## Definition of “non-use” scenario

[Insert text here]

## Information for the length of the review period

[Insert text here]

# impacts OF GRANTING AUTHORISATION

## Human health and/or environmental impacts

[Insert text here]

### Number of people exposed

[Insert text here]

### Impact on the environment

[Insert text here]

**Table X: Summary of additional statistical <endpoint> cases:**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Excess <endpoint> risk**2 | **Number of exposed people** | **Estimated statistical <endpoint> cases** | **Value per statistical <endpoint> case** | **Monetised excess risk per year1** |
| Workers | | | | | |
| Directly exposed workers3 |  |  |  |  |  |
| Indirectly exposed workers4 |  |  |  |  |  |
| Sub-total |  |  |  |  |  |
| General population | | | | | |
| Local |  |  |  |  |  |
| Regional |  |  |  |  |  |
| Sub-total |  |  |  |  |  |
| **Total** |  |  |  |  |  |
| Latency(years) |  | | | | |

Notes:

1. Annualised to a typical year based on the time horizon used in the SEA;
2. Excess risk is estimated over a lifetime working exposure (typically 40 years) and via the environment over a typical lifetime exposure (typically 70 years);
3. Directly exposed workers perform tasks described in the worker contributing scenarios, typically based on 8 hour Time Weighted Average (TWA) of a representative worker;
4. Indirectly exposed workers (bystanders) do not use the substance;

## Economic impacts

[Insert text here]

## Social impacts

[Insert text here]

## Wider economic impacts

[Insert text here]

**Table X: Socio-economic benefits of continued use**

|  |  |
| --- | --- |
| **Description of major impacts** | **Quantification of impacts**  **[annualised to € million per year]** |
| **1. Benefits to the applicant(s) and/or their supply chain** | |
| * 1. Avoided profit loss due to investment and/or production costs related to the adoption of an alternative |  |
| * 1. Avoided profit loss due to ceasing the use applied for[[1]](#footnote-1) |  |
| * 1. Avoided relocation or closure cost |  |
| * 1. Avoided residual value of capital |  |
| * 1. Avoided additional cost for transportation, quality testing, etc. |  |
| **Sum of benefits to the applicant(s) and / or their supply chain** |  |
| **2. Quantified impacts of the continuation of the SVHC use applied for on other actors** | |
| * 1. Avoided net job loss in the affected industry[[2]](#footnote-2) |  |
| * 1. Foregone spill-over impact on surplus of alternative producers |  |
| * 1. Avoided consumer surplus loss (e.g. because of inferior quality, higher price, reduced quantity, etc.) |  |
| * 1. Avoided other societal impacts (e.g. avoided CO2 emissions or securing the production of drugs) |  |
| **Sum of impacts of continuation of the use applied for** |  |
| **3. Aggregated socio-economic benefits (1+2)** |  |

# COMBINED ASSESSMENT OF IMPACTS

## Comparison of impacts

[Insert text here]

**Table X: Comparison of socio-economic benefits and risks of continued use**

|  |  |  |  |
| --- | --- | --- | --- |
| **Socio-economic benefits of continued use** | | **Monetised excess risks associated with continued use** | |
| Benefits to the applicant(s) and/or their supply chain [annualised to € million per year] |  | Monetised excess risks to workers directly exposed in the use applied for [annualised to € million per year] |  |
| Quantified impacts of the continuation of the SVHC use applied for on other actors |  | Monetised excess risks to the general population and indirectly exposed workers [annualised to € million per year] |  |
| Additional qualitatively assessed impacts |  | Additional qualitatively assessed risks |  |
| Aggregated socio-economic benefits  [annualised to € million per year] |  | Aggregated monetised excess risk [annualised to € million per year] |  |

**Table X: Benefit/ risk summary**

|  |  |
| --- | --- |
| Net benefits (€) |  |
| Benefit/monetised risk ratio |  |

**Table X: Cost of non-use per kg and year (for PBT/vPvB substances and endocrine disruptors)**

|  |  |
| --- | --- |
|  | **Per year** |
| Total cost (€)[annualised to € million per year] |  |
| Total emissions (kg) |  |
| Ratio (€/kg) |  |

Notes:

1. “Total cost” (of non-authorisation) = Benefit of authorisation
2. “Total emissions” (if authorisation is granted) = Estimated emissions to the environment, kg per year from Section 10.2 of the CSR
3. “Ratio” = Total cost/Total emissions
4. Annualised to a typical year based on the time horizon that you used in the analysis

## Distributional impacts

[Insert text here]

**Table X: Distributional impacts**

|  |  |  |
| --- | --- | --- |
| **Affected group1** | **Economic impact** | **Health and environmental impact** |
| **Economic operator** | | |
| Applicant |  |  |
| Suppliers of alternatives in the EU |  |  |
| Suppliers of alternatives outside the EU |  |  |
| Competitors in the EU |  |  |
| Competitors outside the EU |  |  |
| Customer group 1 (identify2) |  |  |
| Customer group 2 (identify) |  |  |
| Public at large in the EU (identify) |  |  |
| **Geographical scope** | | |
| Region or Member State x |  |  |
| Region or Member State y |  |  |
| **Within the applicant’s business** | | |
| Employers/Owners |  |  |
| Exposed workers |  |  |
| Non-exposed employees |  |  |

Notes:

1 Adapt the groups as relevant for your application.

2 Identify group or groups as relevant. These may comprise the downstream or end users of the substance or the final customers of the products.

Severity of impacts: either monetary [annualised to € million per year] or using scale high (+++ or ---), medium (++ or --), low (+ or -) or not applicable (n/a)

## Uncertainty analysis

[Insert text here]

# CONCLUSIONs

[Insert text here]

# REFERENCES

[Provide list of references]

Annex – Justifications for ConfidentialiTy Claims[[3]](#footnote-3)

[Insert text and table here]

|  |  |  |
| --- | --- | --- |
| **Blanked out item reference** | **Page number** | **Justification for blanking** |
| Blank #1 | … | …. |
| Blank # 2 | … | … |
| … | … | … |

# APPENDIXES

## Appendix 1 Consultations

[Insert consultations appendices here]

\_\_\_\_\_\_\_

## Additional appendices

[Insert additional appendices here]

1. Profit losses to be counted in only for the first [x] years, see SEAC note on economic surplus changes (not yet available). [↑](#footnote-ref-1)
2. Job losses to be accounted for only for the arithmetic mean period of unemployment in the concerned region/country as outlined in the SEAC paper on the valuation of job losses (See [The social cost of unemployment](https://echa.europa.eu/documents/10162/13555/seac_unemployment_evaluation_en.pdf/af3a487e-65e5-49bb-84a3-2c1bcbc35d25) and [Valuing the social costs of job losses in applications for authorisation](https://echa.europa.eu/documents/10162/13555/unemployment_report_en.pdf/e0e5b4c2-66e9-4bb8-b125-29a460720554)). [↑](#footnote-ref-2)
3. This annex will not be made publicly available as part of the broad information on uses package [↑](#footnote-ref-3)